Nicola Veronese1,2, Ai Koyanagi3, Brendon Stubbs4,5,6, Marco Solmi2,7, Michele Fornaro8, Brisa S Fernandes9,10, Christoph Mueller11, Trevor Thompson11, André F Carvalho12, Stefania Maggi1. 1. National Research Council, Neuroscience Institute, Aging Branch, Padova, Italy. 2. Institute for clinical Research and Education in Medicine (IREM), Padova, Italy. 3. Research and Development Unit, Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, Barcelona, Spain. 4. South London and Maudsley NHS FoundationTrust, London, UK. 5. Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. 6. Faculty of Health, Social Care and Education, Anglia Ruskin University, Chelmsford, UK. 7. Department of Neurosciences, University of Padova, Padova, Italy. 8. New York Psychiatric Institute, Columbia University, New York, NY, USA. 9. IMPACT Strategic Research Centre, School of Medicine, and Barwon Health, Deakin University, Geelong, Australia. 10. Laboratory of Calcium Binding Proteins in the Central Nervous System, Department of Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. 11. Faculty of Education and Health, University of Greenwich, London, UK. 12. Translational Psychiatry Research Group, Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceara, Fortaleza, Brazil.
Abstract
OBJECTIVE: Aspirin exhibits anti-atherosclerotic and anti-inflammatory properties-two potential risk factors for depression. The relationship between aspirin use and depression, however, remains unclear. We investigated whether the aspirin use is associated with a decreased incidence of depressive symptoms in a large North American cohort. METHODS: Data from the Osteoarthritis Initiative dataset, a multicenter, longitudinal study on community-dwelling adults was analyzed. Aspirin use was defined through self-report in the past 30 days and confirmed by a trained interviewer. Incident depressive symptoms were defined as a score of ≥16 in the 20-item Center for Epidemiologic Studies-Depression scale. RESULTS: A total of 137 participants (mean age 65 y, 55.5% female) were using aspirin at baseline. Compared with 4003 participants not taking aspirin, no differences in Center for Epidemiologic Studies-Depression at baseline were evident (P = .65). After a median follow-up time of 8 years, the incidence of depressive symptoms was similar in those taking aspirin at baseline (43; 95% CI, 3-60) and in aspirin nonusers (38; 95% CI, 36-41) per 1000 y; log-rank test = 0.63). Based on Cox's regression analysis adjusted for 11 potential confounders, aspirin use was not significantly associated with the development of depressive symptoms (hazard ratio = 1.12; 95% CI, 0.78-1.62; P = .54). Adjustment for propensity scores or the use of propensity score matching did not alter the results. CONCLUSION: Our study found that prescription of aspirin offered no significant protection against incident depressive symptoms. Whether aspirin is beneficial in a subgroup of depression with high levels of inflammation remains to be investigated in future studies.
OBJECTIVE:Aspirin exhibits anti-atherosclerotic and anti-inflammatory properties-two potential risk factors for depression. The relationship between aspirin use and depression, however, remains unclear. We investigated whether the aspirin use is associated with a decreased incidence of depressive symptoms in a large North American cohort. METHODS: Data from the Osteoarthritis Initiative dataset, a multicenter, longitudinal study on community-dwelling adults was analyzed. Aspirin use was defined through self-report in the past 30 days and confirmed by a trained interviewer. Incident depressive symptoms were defined as a score of ≥16 in the 20-item Center for Epidemiologic Studies-Depression scale. RESULTS: A total of 137 participants (mean age 65 y, 55.5% female) were using aspirin at baseline. Compared with 4003 participants not taking aspirin, no differences in Center for Epidemiologic Studies-Depression at baseline were evident (P = .65). After a median follow-up time of 8 years, the incidence of depressive symptoms was similar in those taking aspirin at baseline (43; 95% CI, 3-60) and in aspirin nonusers (38; 95% CI, 36-41) per 1000 y; log-rank test = 0.63). Based on Cox's regression analysis adjusted for 11 potential confounders, aspirin use was not significantly associated with the development of depressive symptoms (hazard ratio = 1.12; 95% CI, 0.78-1.62; P = .54). Adjustment for propensity scores or the use of propensity score matching did not alter the results. CONCLUSION: Our study found that prescription of aspirin offered no significant protection against incident depressive symptoms. Whether aspirin is beneficial in a subgroup of depression with high levels of inflammation remains to be investigated in future studies.
Authors: Peter M Rothwell; Michelle Wilson; Carl-Eric Elwin; Bo Norrving; Ale Algra; Charles P Warlow; Tom W Meade Journal: Lancet Date: 2010-10-21 Impact factor: 79.321
Authors: C Pizzi; L Santarella; M G Costa; O Manfrini; M E Flacco; L Capasso; S Chiarini; A Di Baldassarre; L Manzoli Journal: J Biol Regul Homeost Agents Date: 2012 Oct-Dec Impact factor: 1.711
Authors: Marco Solmi; Nicola Veronese; Angela Favaro; Paolo Santonastaso; Enzo Manzato; Giuseppe Sergi; Christoph U Correll Journal: Psychoneuroendocrinology Date: 2014-10-08 Impact factor: 4.905
Authors: Meike W Vernooij; Mendel D M Haag; Aad van der Lugt; Albert Hofman; Gabriel P Krestin; Bruno H Stricker; Monique M B Breteler Journal: Arch Neurol Date: 2009-04-13